NASDAQ:GANX Gain Therapeutics Q1 2026 Earnings Report $1.87 -0.03 (-1.58%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.90 +0.03 (+1.60%) As of 08:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gain Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.13Beat/MissN/AOne Year Ago EPSN/AGain Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.03 millionBeat/MissN/AYoY Revenue GrowthN/AGain Therapeutics Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Gain Therapeutics Earnings HeadlinesGain Flat Ahead of Arizona ConferenceApril 24, 2026 | baystreet.caGain Therapeutics, Inc. to Present Update on Parkinson’s Disease Drug GT-02287 at 3rd International GBA1 Meeting 2026April 24, 2026 | quiverquant.comQThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.May 6 at 1:00 AM | Behind the Markets (Ad)Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026April 24, 2026 | globenewswire.comGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateMarch 26, 2026 | globenewswire.comGain Therapeutics, Inc. CEO Gene Mack to Speak at 38th Annual ROTH ConferenceMarch 19, 2026 | quiverquant.comQSee More Gain Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email. Email Address About Gain TherapeuticsGain Therapeutics (NASDAQ:GANX) (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects. Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity. In addition to its clinical program, the company is advancing preclinical pipelines targeting Parkinson’s disease and other central nervous system disorders. Using structure-based design and high-throughput screening, Gain seeks to expand its pipeline across multiple indications with high unmet medical need. Headquartered in Geneva, Switzerland, with research operations in Massachusetts, Gain Therapeutics was founded in 2015 and has since established collaborations with academic centers and industry partners to support its discovery and development efforts. The company is led by a management team with experience in biotechnology, pharmaceutical development, and protein science, guiding Gain through translational research toward clinical validation.View Gain Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It. Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
